|
89
|
230
|
6cn6A |
Rorc2 lbd complexed with compound 34 |
|
87
|
231
|
6cn5A |
Human retenoid-related orphan receptor-gamma ligand- binding domain in complex with indole ligand cp9b in inverse agonist conformation |
|
88
|
246
|
6chzA |
Estrogen receptor alpha y537s bound to antagonist h3b-9224. |
|
87
|
241
|
6cbzA |
Estrogen receptor alpha ligand binding domain y537s mutant in complex with estradiol and grip peptide |
|
90
|
242
|
6cbzB |
Estrogen receptor alpha ligand binding domain y537s mutant in complex with estradiol and grip peptide |
|
87
|
238
|
6c42A |
Estrogen receptor alpha ligand binding domain in complex with op1156 |
|
95
|
278
|
6c5qA |
Pparg lbd bound to sr10171 |
|
107
|
318
|
6bnsA |
Structure of human pregnane x receptor ligand binding domain bound tethered with src co-activator peptide and compound 25a aka bicyclic hexafluoroisopropyl 2 alcohol sulfonamides |
|
82
|
228
|
6bn6A |
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as rorgt/rorc inverse agonists |
|
74
|
236
|
6b0fA |
Estrogen receptor alpha ligand binding domain in complex with lsz102 |
|
89
|
228
|
6b31A |
Structure of rorgt in complex with a novel inverse agonist 2 |
|
86
|
251
|
5zweA |
Covalent bond formation between histidine of vitamin d receptor (vdr) and a full agonist having a vinyl ketone group via conjugate addition reaction |
|
95
|
251
|
5zwfA |
Covalent bond formation between histidine of vitamin d receptor (vdr) and a full agonist having a enone with a beta methyl group via conjugate addition reaction |
|
95
|
270
|
6augA |
Crystal structure of human ppargamma ligand binding domain in complex with sr16832 |
|
97
|
251
|
5zwiA |
Interaction between vitamin d receptor (vdr) and a ligand having a dienone group |
|
97
|
272
|
6an1A |
Crystal structure of the complex between ppargamma lbd and the ligand am-879 |
|
88
|
251
|
5zwhA |
Covalent bond formation between histidine of vitamin d receptor (vdr) and a full agonist having an ene-ynone group via conjugate addition reaction |
|
99
|
270
|
6aviA |
Crystal structure of human ppargamma ligand binding domain in complex with gw9662 and nonanoic acid |
|
89
|
243
|
5yp5A |
Crystal structure of rorgamma complexed with src2 and compound 5d |
|
69
|
231
|
5z12B |
A structure of fxr/rxr |
|
84
|
228
|
5z12A |
A structure of fxr/rxr |
|
94
|
243
|
5yp6A |
Rorgamma (263-509) complexed with src2 and compound 6 |
|
102
|
274
|
5ycnA |
Human ppargamma ligand binding domain complexed with lobeglitazone |
|
103
|
267
|
5y7xA |
Human peroxisome proliferator-activated receptor (ppar) delta in complexed with a potent and selective agonist |
|
103
|
274
|
5ycpA |
Human ppargamma ligand binding domain complexed with rosiglitazone |
|
104
|
270
|
5y2tA |
Structure of ppargamma ligand binding domain - lobeglitazone complex |
|
89
|
250
|
5xuqA |
Crystal structure of vdr-lbd complexed with an antagonist, 2-methylidene-19,26,27-trinor-22-(s)-butyl-1-hydroxy-25-oxo-25-(1h-pyrrol-2-yl)- vitamin d3 |
|
105
|
267
|
5xmxA |
Co-crystal structure of inhibitor compound in complex with human ppardelta lbd |
|
101
|
250
|
5xzfA |
Vitamin d receptor with a synthetic ligand adro1 |
|
101
|
251
|
5xpmA |
Crystal structure of vdr-lbd complexed with 22s-butyl-25rs-(hydroxyphenyl)-25-methoxy-2-methylidene-19,26,27-trinor-1-hydroxyvitamin d3 |
|
89
|
228
|
5x8qA |
Crystal structure of the mutant human ror gamma ligand binding domain with rockogenin. |
|
85
|
240
|
5wgqA |
Estrogen receptor alpha ligand binding domain in complex with estradiol and src2-bcp1 |
|
83
|
228
|
5x8xA |
Crystal structure of the mutant human ror gamma ligand binding domain with compound a. |
|
98
|
244
|
5x8wA |
Crystal structure of the mutant human ror gamma ligand binding domain. |
|
89
|
240
|
5wgdA |
Estrogen receptor alpha ligand binding domain in complex with estradiol and src2-lp1 |
|
94
|
269
|
5wr1A |
Covalent bond formation of bifunctional ligand with hpparg-lbd |
|
100
|
259
|
5vb3A |
X-ray structure of nuclear receptor ror-gammat ligand binding domain + src2 peptide |
|
75
|
198
|
5tbpA |
Crystal structure of rxr-alpha ligand binding domain complexed with synthetic modulator k8003 |
|
90
|
244
|
5tmuA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with 4,4'-(cycloheptylidenemethylene)diphenol |
|
92
|
245
|
5tmvA |
Crystal structure of the er-alpha ligand-binding domain (y537s) in complex with the obhs analog, 4-iodophenyl (1s,2r,4s)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate |
|
98
|
299
|
5nmbA2 |
Structure-activity relationship study of vitamin d analogs with oxolane group in their side chain |
|
96
|
298
|
5mx7A1 |
1a,20s-dihydroxyvitamin d3 vdr complex |
|
93
|
241
|
5c4tA |
Identification of a novel allosteric binding site for rorgt inhibitors |
|
92
|
241
|
5c4oA |
Identification of a novel allosteric binding site for rorgt inhibitors |
|
99
|
251
|
5b41A |
Crystal structure of vdr-lbd complexed with 2-methylidene-19-nor-1a,25-dihydroxyvitamin d3 |
|
100
|
260
|
5b5bA |
Crystal structure of vdr-lbd complexed with 2-methylidene-26,27-diphenyl-19-nor-1,25-dihydroxyvitamin d3 |
|
90
|
250
|
5aauA |
Optimization of a novel binding motif to to (e)-3-(3,5-difluoro-4-((1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1h- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (azd9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist |
|
74
|
240
|
5aavB |
Optimization of a novel binding motif to to (e)-3-(3,5-difluoro-4-((1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1h- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (azd9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist |
|
82
|
239
|
5accA |
A novel oral selective estrogen receptor down-regulator, azd9496, drives tumour growth inhibition in estrogen receptor positive and esr1 mutant models |
|
85
|
249
|
5aavA |
Optimization of a novel binding motif to to (e)-3-(3,5-difluoro-4-((1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1h- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (azd9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist |
